|
|
|
| Efficacy of methotrexate combined with tetrahydrofolic acid intramuscular injection and oral mifepristone for treating scar pregnancy of women with ≤8 gestational weeks |
| Hainan Maternity and Cchild Health Care Hospital, Haikou, Hainan Province, 570206 |
|
|
|
|
Abstract Objective: To evaluate the safety and clinical efficacy of methotrexate combined with tetrahydrofolic acid intramuscular injection and oral mifepristone for treating scar pregnancy of women with ≤8 gestational weeks. Methods: 70 pregnant women with ≤8 gestational weeks were divided into control group and study group according to the random number table (35 cases in each group). The women in the control group were treated with methotrexate intramuscular injection and oral mifepristone, and the women in the study group were treated with methotrexate combined with tetrahydrofolic acid intramuscular injection and oral mifepristone. The levels of serum progesterone (P) and β-human chorionic gonadotropin (HCG) of women were measured before and after the treatment. QLQ-C30 scale was used for assessing quality of life, remission time of clinical symptoms and signs of all women. The clinical efficacy and side effects of women were compared between the two groups. Results: Compared with those before treatment, the levels of serum P and β-hCG, and scores of QLQ-C30 scale of women in both groups had decreased significantly, and those of women in the study groups were lower than those of women in the control group (P<0.05). After treatment, the postoperative bleeding time, hospitalization time, duration ofβ-hCG returned to negative, and menstrual recovery time of women in the study group were 11.9±4.0d, 16.9±3.2d, 16.5±4.5d, and 63.3±5.4d, respectively, which were significant lower than those of women in the control group. The effective rate of women in the study group was 91.4%, which was significant higher than that (71.4%) of women in the control group, but the incidence of fever and leukocyte decline rate were 2.9% and 5.7%, which were significant lower than those (17.1% and 22.9%) of women in the control group (P<0.05). Conclusion: Methotrexate combined with tetrahydrofolic acid intramuscular injection and oral mifepristone for treating women with scar pregnancy has definite curative effect, which can improve the quality of life of women and have less adverse reaction.
|
|
|
|
|
|
|
|
|
